Moderna (Nasdaq: MRNA) has secured a $3.3 billion contract modification from the U.S. Army for additional 200 million filled drug production doses of its SARS-CoV-2 mRNA-1273 vaccine, bringing the total confirmed government order to 500 million doses.
The Department of Defense said Monday the biotechnology company will conduct production work at its Cambridge, Massachusetts facility and complete deliveries by approximately the end of March 2022.
In a Wednesday press release, Moderna noted it aims to hand over 110 million vaccine doses to the government in the fourth quarter of the current calendar year and the remaining 90 million doses in the first quarter of 2022.
The award also includes an option for the government to buy other Moderna COVID-19 vaccine candidates.
Army Contracting Command obligated the full contract modification amount from the service branch’s research, development, test and evaluation funds at the time of the award.
To date, Moderna has supplied 217 million COVID-19 vaccine doses to the U.S. government.